Table 2.
Summary of cytokines measurable in initial dialysate samples from at least 8 of 10 study patients
| Cytokine | Pt numberb | Brain interstitial fluid |
Serum |
||||
|---|---|---|---|---|---|---|---|
| Baselinec | 48 hc | 96 hc | Baselinec | 48 hc | 96 hc | ||
| IL-8a | 10,10,7,7,6,6 | 7,949.2 (303.7–25,650) | 399.5 (69.0–2,217.7) | 378.5 (14.8–5,715.3) | 61.8 (24.0–1,077.7) | 39.5 (20.1–892.0) | 37.3 (21.9–138.0) |
| IP-10a | 10,10,7,7,6,6 | 87.8 (9.3–2,359) | 115.6 (4.4–2,720.2) | 56.0 (2.7–131.2) | 23.5 (12.4–173) | 18.6 (10.4–141.5) | 17.0 (10.9–115.0) |
| MCP-1a | 10,10,7,7,6,6 | 13,864.7 (3,453.8–24,360) | 2,426.1 (61.5–7,819.8) | 2,139.1 (38.8–7,771.8) | 297.2 (190.1–435.6) | 229.0 (101.6–318.8) | 414.8 (179.3–464.8) |
| MIP-1βa | 10,10,7,7,6,6 | 577.8 (47.1–2,580.0) | 55.5 (15.6–307.7) | 51.1 (7.4–217.9) | 101.3 (46.0–1,163.1) | 70.5 (40.5–96–0) | 55.8 (30.2–122.7) |
| IL-6a | 10,10,7,7,6,4 | 1,108.5 (248.6–6,900) | 309.0 (39.3–1,160.6) | 76.0 (8.3–836.5) | 12.4 (3.0–22.2) | 9.4 (4.2–15.0) | 8.9 (3.7–19.2) |
| IL12p40p70a | 10,9,6,7,6,6 | 34.8 (8.2–205.2) | 6.8 (3.9–23.0) | 6.9 (3.4–14.6) | 109.0 (53.9–495.0) | 95.3 (57.5–453.5) | 98.2 (50.1–462.3) |
| IL-1RA | 10,9,6,6,5,5 | 627.1 (91.0–2,458.8) | 110.2 (27.8–708.4) | 115.3 (18.6–844.1) | 158.3 (112.0–693.5) | 108.5 (60.1–159.6) | 88.8 (58.8–226.0) |
| MIP-1αa | 10,8,7,7,6,6 | 169.2 (53.1–513.4) | 20.5 (9.3–76.2) | 10.6 (5.4–64.2) | 34.4 (9.1–626.9) | 25.7 (7.1–298.7) | 30.5 (7.1–376.2) |
| RANTES | 10,7,1,3,2,1 | 325.5 (13.1–1,638.3) | 48.8 (20.9–92.6) | 18.8 | 8,380 (7,994.0–11,462.9) | 9,412.7 (8,380–10,445.5) | 8,380 |
| IFN-αa | 9,7,3,7,5,6 | 21.9 (14.8–76.8) | 17.2 (5.3–29.1) | 8.6 (7.1–13.1) | 29.6 (22.7–124.9) | 33.3 (25.9–150.4) | 35.4 (32.6–158.2) |
| G-CSFa | 9,7,1,7,4,4 | 66.0 (16.5–2,226.8) | 24.0 (9.4–277.0) | 4.1 | 65.7 (28.4–198.1) | 89.0 (46.7–163.4) | 89.5 (24.6–168.8) |
| IL-2Ra | 9,5,1,7,6,6 | 82.4 (42.5–317.1) | 49.2 (20.1–63.6) | 32.4 | 256.2 (132.9–710.8) | 249.5 (121.2–698.4) | 220.2 (122.5–704.9) |
| VEGFa | 8,7,2,5,4,4 | 11.4 (4.8–46.2) | 6.2 (2.6–17.5) | 5.4 (2.1–8.7) | 3.2 (2.1–22.4) | 3.6 (3.1–10.2) | 4.1 (3.3–10.1) |
| IL-17 | 8,5,3,4,2,3 | 47.2 (16.9–88.3) | 43.4 (11.1–63.5) | 44.8 (37.7–73.3) | 55.7 (10.2–58.8) | 51.1 (47.6–54.7) | 48.0 (15.3–56.3) |
| IL-10 | 8,6,0,6,5,2 | 9.3 (1.8–19.7) | 3.0 (1.6–7.7) | n/d | 5.0 (2.4–11,1) | 3.0 (1.8–21.0) | 5.7 (2.0–9.4) |
| MIG | 8,4,1,6,5,3 | 17.6 (6.8–84.7) | 14.4 (10.4–18.2) | 21.1 | 52.9 (17.8–391.2) | 31.6 (18.2–151.4) | 63.6 (28.4–104.3) |
| IFN-γ | 8,2,0,4,3,3 | 15.1 (2.3–47.9) | 4.3 (2.8–5.8) | n/d | 67.7 (9.1–76.9) | 58.9 (12.1–68.8) | 57.5 (15.8–83.1) |
n/d Not detectable
a
Cytokines whose intracerebral levels significantly decreased over the 96 h study period
b
The number of patient samples represented in each column (baseline brain, 48 h brain 96 h brain, baseline serum, 48 h serum 96 h serum) respectively
c
Median (range) in units of pg/ml